Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Chuke E. Nwachuku"'
Autor:
Marco J.D. Tangelder, Chuke E. Nwachuku, Gary M. Ansel, John H. Rundback, George L. Adams, Iris Baumgartner, Michele F. Mercur, Frans L. Moll, Michael A. Grosso, Michael R. Jaff, Min Lin, Thomas Zeller, Erich Minar
Publikováno v:
Journal of Endovascular Therapy
Moll, Frans; Baumgartner, Iris; Jaff, Michael; Nwachuku, Chuke; Tangelder, Marco; Ansel, Gary; Adams, George; Zeller, Thomas; Rundback, John; Grosso, Michael; Lin, Min; Mercur, Michele F; Minar, Erich (2018). Edoxaban Plus Aspirin vs Dual Antiplatelet Therapy in Endovascular Treatment of Patients With Peripheral Artery Disease: Results of the ePAD Trial. Journal of endovascular therapy, 25(2), pp. 158-168. International Society of Endovascular Specialists 10.1177/1526602818760488
Moll, Frans; Baumgartner, Iris; Jaff, Michael; Nwachuku, Chuke; Tangelder, Marco; Ansel, Gary; Adams, George; Zeller, Thomas; Rundback, John; Grosso, Michael; Lin, Min; Mercur, Michele F; Minar, Erich (2018). Edoxaban Plus Aspirin vs Dual Antiplatelet Therapy in Endovascular Treatment of Patients With Peripheral Artery Disease: Results of the ePAD Trial. Journal of endovascular therapy, 25(2), pp. 158-168. International Society of Endovascular Specialists 10.1177/1526602818760488
PURPOSE To report a randomized study that investigated the safety (risk of major bleeds) and potential efficacy of edoxaban, an oral anticoagulant that targets the major components of arterial thrombi, to prevent loss of patency following endovascula
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b244c43c7ae92782f76d9022976870dc
https://doi.org/10.1177/1526602818760488
https://doi.org/10.1177/1526602818760488
Autor:
Iris Baumgartner, Chuke E. Nwachuku, Michael R. Jaff, Anil Duggal, Michael A. Grosso, George L. Adams, Frans L. Moll, Gary M. Ansel, Erich Minar, Minggao Shi, Marco J.D. Tangelder, Michele Mercuri
Publikováno v:
Journal of Endovascular Therapy, 22(2), 261. International Society of Endovascular Specialists
Compared with the coronary setting, knowledge about antithrombotic therapies after endovascular treatment (EVT) is inadequate in patients with peripheral artery disease (PAD). Based on a review of trials and guidelines, which is summarized in this ar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d6cc16fb8903326b69daf55f71132010
https://dspace.library.uu.nl/handle/1874/339668
https://dspace.library.uu.nl/handle/1874/339668
Autor:
Lakshmanan Krishnamurti, Chuke E. Nwachuku, Andrew L. Frelinger, Lori E. Heath, Abdullah Kutlar, Kenneth J. Winters, Lillian McMahon, Kenneth I. Ataga, Denis Soulières, Enrico M. Novelli, Theodore Wun, Joseph A. Jakubowski, Charles Knupp, Jeffrey S. Riesmeyer, John J. Strouse, Chunmei Zhou
Publikováno v:
Wun, Ted; Soulieres, Denis; Frelinger, Andrew L; Krishnamurti, Lakshmanan; Novelli, Enrico M; Kutlar, Abdullah; et al.(2013). A double-blind, randomized, multicenter phase 2 study of prasugrel versus placebo in adult patients with sickle cell disease. Journal of Hematology & Oncology, 6(1), 17. doi: http://dx.doi.org/10.1186/1756-8722-6-17. Retrieved from: http://www.escholarship.org/uc/item/9h4873cq
Journal of Hematology & Oncology
Journal of Hematology & Oncology, Vol 6, Iss 1, p 17 (2013)
Journal of Hematology & Oncology
Journal of Hematology & Oncology, Vol 6, Iss 1, p 17 (2013)
Background Platelet activation has been implicated in the pathogenesis of sickle cell disease (SCD) suggesting antiplatelet agents may be therapeutic. To evaluate the safety of prasugrel, a thienopyridine antiplatelet agent, in adult patients with SC
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::868aac9f19792803723f2fbc1c9473f2
http://www.escholarship.org/uc/item/9h4873cq
http://www.escholarship.org/uc/item/9h4873cq
Autor:
Kellie J. Windle, Kenneth J. Winters, Eileen M. Rose, David P. Lee, Hsini Liao, Chuke E. Nwachuku, Thomas S. Bowman, Kirk N. Garratt, Keith D. Dawkins
Publikováno v:
American heart journal. 163(2)
Background Observational studies of new coronary stents are necessary to assess performance in a variety of complex patient and lesion types. Furthermore, the optimal dose and duration of thienopyridine treatment is unclear, particularly in patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ab978d50f79ba49c62518d6b5309b2e0
https://pubmed.ncbi.nlm.nih.gov/22305829
https://pubmed.ncbi.nlm.nih.gov/22305829
Autor:
Denis Soulières, Kenneth I. Ataga, Theodore Wun, Lakshmanan Krishnamurti, Kenneth J. Winters, Jeffrey S. Riesmeyer, Abdullah Kutlar, Chunmei Zhou, Joseph A. Jakubowski, Chuke E. Nwachuku, Lori E. Heath
Publikováno v:
Blood. 118:847-847
Abstract 847FN2 Introduction: Platelet activation may play a role in the pathogenesis of various complications related to sickle cell disease (SCD). Older studies of antiplatelet agents in reducing the frequency and severity of pain in SCD have been
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::68b8c61c0cbe5660dbf7a2662b807e17
https://doi.org/10.1182/blood.v118.21.847.847
https://doi.org/10.1182/blood.v118.21.847.847
Autor:
Jeffrey S. Riesmeyer, Theodore Wun, Chuke E. Nwachuku, Chunmei Zhou, Lori E. Heath, Charles Knupp, Joseph A. Jakubowski, John J. Strouse, Kenneth J. Winters, Lillian McMahon
Publikováno v:
Blood. 118:2127-2127
Abstract 2127 Introduction: Activation of the hemostatic cascade and platelet activation in particular, has been implicated in the pathogenesis of sickle cell disease (SCD). Prasugrel is a third generation thienopyridine antiplatelet agent, an oral P
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1e7e4772f6d3d228d4d03e2a6aaa99e7
https://doi.org/10.1182/blood.v118.21.2127.2127
https://doi.org/10.1182/blood.v118.21.2127.2127